Explore the mechanism of Shengma-Gegen drug pair on hepatitis B virus based on network pharmacology

Guozhe Zhang,Chunmiao Chen,Yiyu Qin,Jianwei Ji
DOI: https://doi.org/10.21203/rs.3.rs-59583/v1
2020-08-18
Abstract:Abstract Background Sheng-Ma-Ge-Gen-Tang (SMGGT; 升麻葛根汤) is a famous prescription of traditional Chinese medicine used against measles of children for many hundreds of years. And its anti-hepatitis B virus (HBV) activity has been justified in clinical, however, the function substances and the mechanisms have not been studied yet. Methods The latent active compounds of Cimicifugae Rhizoma (Shengma)-Radix Puerariae (Gegen) drug pair were searched, and excavated their related targets. Then seek the targets of HBV through three network databases. The drug-disease targets of protein-protein interaction (PPI) data was carried out. The drug-disease targets were enriched by gene ontology (GO) enrichment and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis. Subsequently, anti-HepG2.2.15 cytotoxicity and anti-HBV experiments were performed on the aqueous and ethanol extracts of Shengma-Gegen in vitro to test and verify their anti-HBV activities. Results GO enrichment indicated biological processes (cellular response to lipid, cellular response to organic cyclic compound, etc.), cellular components (vesicle lumen, cytoplasmic vesicle lumen, etc.) and molecular function (kinase binding, steroid binding, etc.). Many cancer-related pathways were enriched in KEGG pathway analysis. Also got some virus and bacteria diseases. A KEGG-targets network showed that RAF1, CCND1, BCL2, and EGFR might be the core targets. Cytotoxicity of Shengma and Gegen to HepG2.2.15 are in proportion to their concentrations. Shengma and Gegen aqueous and ethanol extracts exhibited a curtain extant anti-HBV-DNA activity. Conclusions Shengma-Gegen showed not only anti-HBV activity but also anti-tumor and anti-viral activities, which need to be tested in the future.
What problem does this paper attempt to address?